Adefovir is a nucleoside analog with activity against a broad spectrum of retroviruses and herpes viruses, including important human pathogens such as HIV-1 and HIV-2, HSV-1 and HSV-2, and CMV. Nelfinavir is a selective, nonpeptide inhibitor of HIV protease with significant antiviral activity measured in cell culture and animal models of HIV infection. Phase I/II clinical trials of nelfinavir indicate that nelfinavir adminsitration leads to substantial decreases in plasma concentrations of HIV-1 RNA and increases of CD4-lymphocytes. The purpose of this study is to evaluate novel, multiple drug combinations with adefovir dipivoxil as par tof a triple combination therapy with nelfinavir and reverse transcriptase inhibitors in pediatric clinical use. The safety and tolerability, the antiviral and immunorestorative effects of the two groups will be compared.
Showing the most recent 10 out of 211 publications
